Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

August 9, 2024 0

Akero Therapeutics Q2 and Business Update Akero Therapeutics (AKRO) reported second-quarter financial results for the period …

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update

August 7, 2024 0

Exelixis Q2 Results and Corporate Update Yesterday, Aug. 6, 2024, Exelixis, (EXEL) reported financial results for …

Serious is the Impact of Bad Circumstances

August 6, 2024 0

The Impact of Bad Circumstances Since early year 2024, in every Prohost Letter we have posted, …

Adaptimmune Therapeutics: A First Approved Treatment of Unresectable or Metastatic Synovial Sarcoma

August 2, 2024 0

Adaptimmune Therapeutics Adaptimmune Therapeutics plc (ADAP) announced that the U.S. FDA has accelerated the approval of …

Anavex Life Sciences: Phase IIb/III Trial Results of Blarcamesine Presented at Alzheimer’s Association Conference

July 29, 2024 0

Anaves Life Sciences Trial Results of Blarcamesine Anavex Life Sciences (AVXL) presented comprehensive results from a …

Viking Therapeutics Reports Promising News

July 25, 2024 0

Viking Therapeutics Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class …

Ionis Pharmaceuticals Announces Positive Detailed Results from the HALOS Study of ION582

July 23, 2024 0

Ionis Pharmaceuticals in the NEWS Yesterday, July 22, 2024, Ionis Pharmaceuticals (IONS) announced positive results from the …

Pliant Therapeutics: Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial of Bexotegrast

July 16, 2024 0

Pliant Therapeutics Pliant Therapeutics is a late-stage biopharmaceutical company focusing on the discovery and development of …

Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

July 16, 2024 0

Lexeo Therapeutics in the NEWS On July 15, 2024, Lexeo Therapeutics (LXEO) announced positive interim data …

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

July 11, 2024 0

Kazia Therapeutics in the NEWS Sydney, July 10, 2024, Kazia Therapeutics Limited (KZIA) - an oncology-focused …

Illumina Acquired Fluent BioSciences to Accelerate Single-Cell Analysis and Discovery to a Broader Customer Base

July 10, 2024 0

Illumina Inc The latest take over by Illumina, Inc. (ILMN) has been a company with advanced …

Advanced Micro Devices to Buy the Largest Private AI Lab in Europe

July 10, 2024 0

Advanced Micro Devices in the NEWS Advanced Micro Devices (AMD) today announced the signing of a …

The European Commission Approved Regeneron Product Dupixent® as Maintenance Treatment for Adults with Uncontrolled COPD

July 5, 2024 0

Regeneron in the NEWS Regeneron Pharmaceuticals (REGN) and Sanofi (SNY . . . This content is …

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat

July 2, 2024 0

Merck in the NEWS Merck Pharmaceuticals (MRK), known as Merck, Sharp & Dohme (MSD) outside the …

SCG Cell Therapy: FDA Approved IND Application of Product SCG142 to Initiate Phase 1/2 Clinical Trial for A Next Generation HPV and its cancers.

July 1, 2024 0

SCG Cell Therapy FDA Approval SCG Cell Therapy Pte Ltd (SCG) is a biotech company developing …

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612 in Parkinson’s Disease at 10th Congress of the European Academy of Neurology

June 28, 2024 0

From Mitsubishi Tanabe Pharma America Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update

Serious is the Impact of Bad Circumstances

Adaptimmune Therapeutics: A First Approved Treatment of Unresectable or Metastatic Synovial Sarcoma

Anavex Life Sciences: Phase IIb/III Trial Results of Blarcamesine Presented at Alzheimer’s Association Conference

Viking Therapeutics Reports Promising News

Ionis Pharmaceuticals Announces Positive Detailed Results from the HALOS Study of ION582

Pliant Therapeutics: Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial of Bexotegrast

Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Illumina Acquired Fluent BioSciences to Accelerate Single-Cell Analysis and Discovery to a Broader Customer Base

Advanced Micro Devices to Buy the Largest Private AI Lab in Europe

The European Commission Approved Regeneron Product Dupixent® as Maintenance Treatment for Adults with Uncontrolled COPD

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat

SCG Cell Therapy: FDA Approved IND Application of Product SCG142 to Initiate Phase 1/2 Clinical Trial for A Next Generation HPV and its cancers.

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612 in Parkinson’s Disease at 10th Congress of the European Academy of Neurology

Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

Nurix Therapeutics: Positive Results from Ongoing Clinical Trial of NX-5948

FDA Approval of argenx Product VYVGART Hytrulo for Patients with CIDP

Alnylam Pharmaceuticals: Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran